九洲药业
(603456)
| 流通市值：133.19亿 | | | 总市值：133.39亿 |
| 流通股本：8.98亿 | | | 总股本：8.99亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,475,743,576.44 | 5,523,418,175.43 | 4,576,609,415.43 | 3,254,642,522.09 |
| 营业收入 | 1,475,743,576.44 | 5,523,418,175.43 | 4,576,609,415.43 | 3,254,642,522.09 |
| 二、营业总成本 | 1,168,180,070.26 | 4,275,834,833.86 | 3,422,488,804.64 | 2,473,324,172.52 |
| 营业成本 | 973,336,263.69 | 3,443,493,393.32 | 2,777,615,988.98 | 2,004,766,888.23 |
| 税金及附加 | 20,367,756.91 | 49,204,012.1 | 32,351,336.89 | 21,130,947.23 |
| 销售费用 | 20,156,806.67 | 82,017,748.26 | 65,159,308.99 | 44,791,768.38 |
| 管理费用 | 108,335,352.12 | 445,926,655.97 | 364,074,011.02 | 267,192,893.44 |
| 研发费用 | 64,871,910.84 | 330,827,761.17 | 239,837,436.31 | 167,026,236.56 |
| 财务费用 | -18,888,019.97 | -75,634,736.96 | -56,549,277.55 | -31,584,561.32 |
| 其中:利息费用 | 8,070,432.96 | 21,733,602.9 | 18,108,655.68 | 10,848,649.73 |
| 其中:利息收入 | 26,450,493.61 | 91,824,261.69 | 64,205,991.87 | 29,860,706.3 |
| 加:公允价值变动收益 | - | - | 5,168,114.86 | 576,410.55 |
| 加:投资收益 | -2,341,966.21 | -19,363,697.54 | -22,720,384.66 | -15,436,435.93 |
| 资产处置收益 | -2,172,342.18 | -2,543,160.71 | -1,520,700.72 | -454,152.75 |
| 资产减值损失(新) | -108,206.84 | -78,203,593.39 | -52,664,633.45 | -52,325,556.38 |
| 信用减值损失(新) | -33,969,218.86 | -20,173,755.07 | -24,939,500.36 | -17,238,689.56 |
| 其他收益 | 11,114,786.63 | 48,472,250.12 | 28,407,949.2 | 18,509,235 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 280,086,558.72 | 1,175,771,384.98 | 1,085,851,455.66 | 714,949,160.5 |
| 加:营业外收入 | 16,616.01 | 8,023,633.72 | 6,703,053.94 | 6,370,783.33 |
| 减:营业外支出 | 61,133.27 | 3,152,981.13 | 4,537,541.59 | 3,587,378.31 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 280,042,041.46 | 1,180,642,037.57 | 1,088,016,968.01 | 717,732,565.52 |
| 减:所得税费用 | 43,869,153.92 | 149,270,261.88 | 123,580,385.24 | 96,411,773.12 |
| 六、净利润 | 236,172,887.54 | 1,031,371,775.69 | 964,436,582.77 | 621,320,792.4 |
| 持续经营净利润 | 236,172,887.54 | 1,031,371,775.69 | 964,436,582.77 | 621,320,792.4 |
| 归属于母公司股东的净利润 | 236,758,875.39 | 1,033,255,687.14 | 966,770,643.95 | 621,727,529.68 |
| 少数股东损益 | -585,987.85 | -1,883,911.45 | -2,334,061.18 | -406,737.28 |
| (一)基本每股收益 | 0.26 | 1.16 | 1.09 | 0.7 |
| (二)稀释每股收益 | 0.26 | 1.16 | 1.09 | 0.7 |
| 八、其他综合收益 | 2,362,921.59 | 2,052,331.71 | 5,785,327.02 | 6,140,465.48 |
| 归属于母公司股东的其他综合收益 | 2,362,921.59 | 2,052,331.71 | 5,785,327.02 | 6,140,465.48 |
| 九、综合收益总额 | 238,535,809.13 | 1,033,424,107.4 | 970,221,909.79 | 627,461,257.88 |
| 归属于母公司股东的综合收益总额 | 239,121,796.98 | 1,035,308,018.85 | 972,555,970.97 | 627,867,995.16 |
| 归属于少数股东的综合收益总额 | -585,987.85 | -1,883,911.45 | -2,334,061.18 | -406,737.28 |
| 公告日期 | 2024-04-25 | 2024-04-09 | 2023-10-28 | 2023-08-15 |
| 审计意见(境内) | | 标准无保留意见 | | |